BlackThorn Therapeutics Initiates Phase 1 Study of BTRX-335140, an Investigational Kappa Opioid Receptor (KOR) Antagonist Read more
Chugai’s HEMLIBRA Receives Priority Review Status from FDA for Hemophilia A Without Inhibitors Read more
Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B Read more
FDA Approves Mylan and Biocon’s Fulphila (pegfilgrastim-jmdb), the First Biosimilar to Neulasta Read more
Merck’s KEYTRUDA (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy Read more